John E. McCartney

Medicine · Health Sciences

16h-index1.7kcitations28works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(18), Radiopharmaceutical Chemistry and Applications(11), Glycosylation and Glycoproteins Research(7), Protein purification and stability(7), HER2/EGFR in Cancer Research(6)

Publications28 total

DISSEMINATED BLASTOMYCOSIS IN AN IMMUNOCOMPETENT INDIVIDUAL WITH PERICARDIAL INVOLVEMENT: A CASE OF DELAYED DIAGNOSIS
CHEST Journal·2020Open Access
Avidity-Mediated Enhancement of <i>In vivo</i> Tumor Targeting by Single-Chain Fv Dimers
Clinical Cancer Research·2006· 100 citedOpen Access
Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7
Kidney International·2002· 95 citedOpen Access
Regeneration of Articular Cartilage Chondral Defects by Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in Sheep
Growth Factors·2001· 95 cited
Human Articular Chondrocytes Express Osteogenic Protein-1
Journal of Histochemistry & Cytochemistry·2000· 111 cited
Biological Repair of Thyroid Cartilage Defects by Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in Dog
Growth Factors·2000· 14 cited
Cartilage-Derived Morphogenetic Proteins and Osteogenic Protein-1 Differentially Regulate Osteogenesis
Journal of Bone and Mineral Research·1998· 156 citedOpen Access
Single-chain Fv radioimmunotargeting.
PubMed·1996· 41 cited
Determinants of selective tumor targeting by single-chain Fv molecules
Immunotechnology·1996
Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation.
PubMed·1995· 23 cited
Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers.
PubMed·1995· 22 cited
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration
Cancer Immunology Immunotherapy·1995· 12 citedOpen Access
Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide.
Proceedings of the National Academy of Sciences·1995· 61 cited
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 Anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration
Cancer Immunology Immunotherapy·1995
In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library
Immunotechnology·1995· 159 cited
Single-Chain Fv Design and Production by Preparative Folding
1995· 16 cited
Engineering disulfide-linked single-chain Fv dimers [(sFv')<sub>2</sub>] with improved solution and targeting properties: anti-digoxin 26–10 (sFv')<sub>2</sub> and anti-c-erbB-2 741F8 (sFv')<sub>2</sub> made by protein folding and bonded through C-terminal cysteinyl peptides
Protein Engineering Design and Selection·1995· 44 cited
Preclinical Studies and Optimization of Specific Tumor Delivery for 741F8 sFv, an Anti-c-erbB-2 Single-Chain Species
International Journal of Pharmacognosy·1995
Mammalian Cell Expression of Single–Chain Fv (sFv) Antibody Proteins and Their C–terminal Fusions with Interleukin–2 and Other Effector Domains
Nature Biotechnology·1994· 61 cited
SINGLE-CHAIN Fv FUSIONS WITH C-TERMINAL CYSTEINE PEPTIDES IsFv′
Journal of Immunotherapy·1994· 1 cited
page 1 of 2Next →

Frequent Co-authors

James S. Huston(17), Hermann Oppermann(14), Gregory P. Adams(12), Mei-Sheng Tai(12), Michael A. Bookman(11), L. L. Houston(11), Walter F. Stafford(10), Louis M. Weiner(8), Axel A. Laminet(6), Robert M. Hudziak(5), I. Fand(4), Ellen J. Wolf(4), M S Tai(4), Jamie Eisenberg(4), Donald Jin(3), Peter Keck(3), James D. Marks(3), Sen Liu(3), E J Wolf(3), L M Weiner(3)